SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

RPG Life Sciences - Quaterly Results

01 Feb 2023 Evaluate
The company witnessed a 13.00% growth in the revenue at Rs. 1306.00 millions for the quarter ended December 2022 as compared to Rs. 1155.80 millions during the year-ago period.Good  Net Profit growth of 30.62% reported above the corresponding previous quarter figure of Rs. 146.30 millions to Rs. 191.10 millioins.OP of the company witnessed a marginal growth to 297.20 millions from 247.10 millions in the same quarter last year.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202212 202112 % Var 202212 202112 % Var 202203 202103 % Var
Sales 1306.00 1155.80 13.00 3943.20 3363.60 17.23 4401.60 3891.40 13.11
Other Income 5.10 6.10 -16.39 29.60 17.30 71.10 29.90 9.10 228.57
PBIDT 297.20 247.10 20.28 897.40 745.80 20.33 893.50 708.40 26.13
Interest 0.70 1.60 -56.25 2.60 4.60 -43.48 5.20 7.90 -34.18
PBDT 296.50 245.50 20.77 894.80 741.20 20.72 888.30 700.50 26.81
Depreciation 39.10 39.30 -0.51 116.10 118.80 -2.27 156.60 164.70 -4.92
PBT 257.40 206.20 24.83 778.70 622.40 25.11 731.70 535.80 36.56
TAX 66.30 59.90 10.68 205.80 182.80 12.58 216.90 135.80 59.72
Deferred Tax -2.90 -1.90 52.63 -0.80 -3.80 -78.95 -10.70 -35.70 -70.03
PAT 191.10 146.30 30.62 572.90 439.60 30.32 514.80 400.00 28.70
Equity 132.30 132.30 0.00 132.30 132.30 0.00 132.30 132.30 0.00
PBIDTM(%) 22.76 21.38 6.44 22.76 22.17 2.64 20.30 18.20 11.51

RPG Life Sciences Share Price

2025.85 126.05 (6.63%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×